Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.
Thomas W. Flaig, MD
Advertisement
Articles by Thomas W. Flaig, MD
Advertisement
Latest Updated Articles
Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder CancerPublished: January 10th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5